Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Examining Integra LifeSciences Holdings Corporation's (NASDAQ:IART) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess IART's latest performance announced on 31 March 2019 and weight these figures against its longer term trend and industry movements.
How Did IART's Recent Performance Stack Up Against Its Past?
IART's trailing twelve-month earnings (from 31 March 2019) of US$83m has jumped 19% compared to the previous year.
However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 33%, indicating the rate at which IART is growing has slowed down. What could be happening here? Well, let’s take a look at what’s going on with margins and whether the entire industry is experiencing the hit as well.
In terms of returns from investment, Integra LifeSciences Holdings has fallen short of achieving a 20% return on equity (ROE), recording 5.9% instead. Furthermore, its return on assets (ROA) of 4.3% is below the US Medical Equipment industry of 6.8%, indicating Integra LifeSciences Holdings's are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Integra LifeSciences Holdings’s debt level, has declined over the past 3 years from 8.3% to 8.2%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 93% to 99% over the past 5 years.
What does this mean?
Integra LifeSciences Holdings's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story. While Integra LifeSciences Holdings has a good historical track record with positive growth and profitability, there's no certainty that this will extrapolate into the future. I suggest you continue to research Integra LifeSciences Holdings to get a more holistic view of the stock by looking at:
- Future Outlook: What are well-informed industry analysts predicting for IART’s future growth? Take a look at our free research report of analyst consensus for IART’s outlook.
- Financial Health: Are IART’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
NB: Figures in this article are calculated using data from the trailing twelve months from 31 March 2019. This may not be consistent with full year annual report figures.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.